Frederiksen Ida Ny, Arnold-Vangsted Andreas, Anguita Rodrigo, Boberg-Ans Lars Christian, Cehofski Lasse Jørgensen, van Dijk Elon H C, Eriksen Nathalie Skovgaard, Ferro Desideri Lorenzo, Grauslund Jakob, Huemer Josef, Iovino Claudio, Künzel Steffen Emil, Ørskov Marie, Pauleikhoff Laurenz J B, Rasmussen Marie Louise Roed, Subhi Yousif
Department of Ophthalmology, Rigshospitalet, Valdemar Hansens Vej 13, 2600, Glostrup, Denmark.
Department of Ophthalmology, University Hospital of Southern Denmark, Vejle Hospital, Vejle, Denmark.
Ophthalmol Ther. 2025 Aug 9. doi: 10.1007/s40123-025-01220-0.
Central serous chorioretinopathy (CSC) is a prevalent exudative maculopathy; however, exact details of its incidence and a global estimate of its annual incidence are lacking. It is paramount to understand the details of the incidence of CSC when discussing its societal and personal impact, the impact of medicine shortages and initiatives for healthcare policies, and organization of retinal service.
In this study, we systematically reviewed the literature on the incidence of CSC and performed meta-analyses to provide an age-stratified estimate of its incidence. By using population statistics from the United Nations Population Division, we were able to estimate the global and country-specific incidence of CSC in 2025 and forecast until 2050.
Seven eligible studies included a total of 324,954 new patients with CSC during their time of investigation. The summary estimate incidence rates per 100,000 person-years were 47.8 (95% confidence interval [CI] 31.7-61.7) for individuals 30-39 years, 71.8 (95% CI 41.7-109.7) for individuals 40-49 years, 58.5 (95% CI 29.9-96.1) for individuals 50-59 years, and 36.2 (95% CI 16.8-62.6) for individuals 60-69 years. We confirmed male sex as a risk factor (odds ratio 2.73, P < 0.0001), and found that male individuals were significantly younger than female individuals at onset of CSC (average difference of 3.30 years, P < 0.0001). We estimated that in 2025, 1.97 million individuals globally will develop CSC, and that the incidence will increase to 2.03 million individuals in 2030, 2.30 million individuals in 2040, and 2.43 million individuals in 2050. The CSC incidence peaked between 40 and 49 years underscoring the significance in working-age individuals.
Numbers presented in this study highlight that CSC is one of the more prevalent maculopathies in our world and underscores the importance of education, research, and healthcare planning related to CSC.
中心性浆液性脉络膜视网膜病变（CSC）是一种常见的渗出性黄斑病变；然而，其发病率的确切细节以及全球年度发病率的总体估计尚不清楚。在讨论CSC对社会和个人的影响、药品短缺的影响、医疗保健政策举措以及视网膜服务组织时，了解CSC发病率的细节至关重要。
在本研究中，我们系统回顾了关于CSC发病率的文献，并进行荟萃分析以提供按年龄分层的发病率估计。通过使用联合国人口司的人口统计数据，我们能够估计2025年全球及各国特定的CSC发病率，并预测至2050年。
七项符合条件的研究在其调查期间共纳入324,954例CSC新患者。每10万人年的汇总估计发病率在30 - 39岁个体中为47.8（95%置信区间[CI] 31.7 - 61.7），40 - 49岁个体中为71.8（95% CI 41.7 - 109.7），50 - 59岁个体中为58.5（95% CI 29.9 - 96.1），60 - 69岁个体中为36.2（95% CI 16.8 - 62.6）。我们确认男性为危险因素（比值比2.73，P < 0.0001），并发现男性CSC发病时明显比女性年轻（平均差异3.30岁，P < 0.0001）。我们估计，2025年全球将有197万人发生CSC，到2030年发病率将增至203万人，2040年为230万人，2050年为243万人。CSC发病率在40至49岁之间达到峰值，突出了对工作年龄个体的重要性。
本研究中的数据表明，CSC是世界上较为常见的黄斑病变之一，并强调了与CSC相关的教育、研究和医疗保健规划的重要性。
